查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676748

环肽市场：按类型、产品、技术、应用和最终用户 - 2025-2030 年全球预测

Cyclic Peptides Market by Type, Product, Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

环肽市场规模在 2024 年预计为 1116.2 亿美元，预计在 2025 年将增长至 1186.2 亿美元，复合年增长率为 6.51%，预计到 2030 年将达到 1629.8 亿美元。

主要市场统计数据
基准年 2024 年 1116.2亿美元
预计 2025 年 1186.2亿美元
预测年份 2030 1629.8亿美元
复合年增长率（%） 6.51%

环肽已成为一类动态和变革性生物分子，正在重塑现代生物医学的典范。其独特的结构特性——增强稳定性并赋予抗酶降解性的环状骨架——使其能够有效地发挥线性肽通常缺乏的功能。随着研究人员和行业专业人士对胜肽化学的深入探索，环肽在从药物设计到诊断创新等各种应用领域的潜力越来越受到认可。

在过去的十年中，对研发的大量投资推动了合成方法和技术平台的快速发展。这项进步为提高胜肽合成的扩充性和精确度铺平了道路，最终有助于改善治疗效果。环肽将自然启发的分子框架与复杂的化学合成相结合，不仅扩展了传统药理学的边界，而且还在肿瘤学、代谢和感染疾病等领域开闢了新的治疗机会。

该领域的不断发展也反映了有机化学、分子生物学和临床研究之间更深层的跨学科合作。随着该领域的成熟，技术创新、市场动态和监管环境的相互作用有望重新定义全球治疗策略。在以下章节中，我们将深入探讨不断变化的行业格局、关键细分见解以及引导当今行业领导者的各个地区和公司的影响力。

改变环肽市场

环状胜肽市场正在经历推动创新和成长的变革。市场发展趋势表明，尖端合成技术越来越多地与尖端筛检方法相结合，以实现快速的发现週期并加速产品开发。溶液和固相合成的改进等先驱技术进步正在重新定义胜肽的生产方式，使其满足特定的临床需求。

除了技术创新之外，受个人化医疗和标靶治疗解决方案日益增长的需求的影响，该领域还经历着重大的监管变革。这些因素正在加速从传统锁状肽模型转向具有卓越功效和安全性的环状结构的转变。

此外，学术研究中心、生技公司和製药公司之间的合作日益增多，形成了共用专业知识和风险的环境。随着此类合作变得越来越普遍，跨学科研究和商业性洞察的融合可能会进一步突破界限。最终，这些转变不仅将重塑竞争格局，而且还将为满足不断变化的患者需求和行业条件的新型、具有成本效益、有影响力的医疗保健解决方案铺平道路。

循环胜肽市场的关键细分见解

为了了解环状胜肽市场的复杂动态，深入研究细分可以从几个方面提供关键见解。分析首先从基于类型的细分开始，将市场分为天然环肽和合成环肽。这种差异突显了创新的双重来源：天然胜肽具有固有的生物相容性，而合成胜肽则提供了结构修饰的机会以增强治疗效果。

依产品类型进一步分类可发现多样化的产品组合，包括抗菌胜肽、荷尔蒙胜肽、免疫调节胜肽和胜肽疫苗。其中，荷尔蒙胜肽的研究越来越深入，特别是从其在胰岛素类似物和肽激素治疗中的应用角度。这种详细的审查将有助于针对可以进一步优化肽疗法的特定治疗领域。

分割的技术方面包括化学合成、杂交技术、溶液相合成、重组 DNA 技术和固相合成。每种方法都透过影响产品品质、扩充性和成本效益来做出独特的贡献。从应用方面来看，市场分为诊断、环境保护、研发和治疗。在这些大类中，诊断学进一步分为生物感测器和免疫测量，研究和开发分为生化分析、药物发现和分子生物学，治疗学则涵盖心血管护理、感染疾病干预、代谢紊乱管理和肿瘤学等广泛领域。

最后，基于最终用户的细分突显了学术机构、生技公司和製药公司所扮演的角色。这种多层次的细分方法不仅强调了决定市场趋势的多种因素的相互作用，而且还强调了每个细分市场的目标策略对于永续成长和创新的重要性。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 慢性病和癌症发生率不断上升，推动创新环状胜肽的需求
      • 以肽疗法为重点的生物製药行业的扩张正在推动对环肽的需求
      • 政府对药物开发的奖励和津贴鼓励探索环肽疗法
    • 限制因素
      • 与胜肽稳定性和生物利用度相关的问题
    • 机会
      • 环肽在环境永续农药设计上的创新应用
      • 创新环肽修饰以改善治疗药物开发的药物动力学
    • 任务
      • 环肽生产的复杂性
  • 市场区隔分析
    • 类型：天然环肽因具有有效调节生物途径的能力而需求量很大。
    • 应用：高特异性和稳定性使得环肽在诊断上的应用越来越广泛。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 环肽市场按类型

  • 天然环肽
  • 合成环肽

第七章 环肽市场（按产品）

  • 抗菌胜肽
  • 荷尔蒙胜肽
    • 胰岛素类似物
    • 肽激素治疗
  • 免疫调节胜肽
  • 胜肽疫苗

第 8 章 环肽市场（按技术）

  • 化学合成
  • 混合技术
  • 液相合成
  • 重组DNA技术
  • 固相合成

第九章 环肽市场按应用

  • 诊断
    • 生物感测器
    • 免疫检测
  • 环境保护
  • 研究与开发
    • 生化分析
    • 药物研发
    • 分子生物学
  • 治疗
    • 心血管
    • 感染疾病
    • 代谢紊乱
    • 肿瘤学

第 10 章 环肽市场（依最终用户）

  • 学术机构
  • 生技公司
  • 製药公司

11. 美洲循环胜肽市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区循环胜肽市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲环肽市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Amgen Inc.
  • AnaSpec
  • Astellas Inc.
  • Asymchem Inc.
  • Bachem Holding AG
  • Bristol-Myers Squibb Company
  • Clariant International Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Insamo
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pepscan Therapeutics BV
  • PeptiDream Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SciTide LLC
  • Zealand Pharma AS
Product Code: MRR-AE420CB152AD

The Cyclic Peptides Market was valued at USD 111.62 billion in 2024 and is projected to grow to USD 118.62 billion in 2025, with a CAGR of 6.51%, reaching USD 162.98 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 111.62 billion
Estimated Year [2025] USD 118.62 billion
Forecast Year [2030] USD 162.98 billion
CAGR (%) 6.51%

Cyclic peptides have emerged as a dynamic and transformative class of biomolecules that are reshaping the paradigms of modern biomedical science. Their unique structural characteristics-circular backbones that impart enhanced stability and resistance to enzymatic degradation-allow them to function effectively where linear peptides often fall short. As researchers and industry experts explore the depths of peptide chemistry, cyclic peptides are increasingly recognized for their potential in diverse applications ranging from drug design to diagnostic innovations.

Over the past decade, substantial investments in research and development have catalyzed breakthroughs in synthetic methodologies and technology platforms. This progress has paved the way for enhanced scalability and precision in peptide synthesis, ultimately contributing to improved therapeutic outcomes. In blending nature-inspired molecular frameworks with sophisticated chemical synthesis, cyclic peptides are not only expanding the boundaries of traditional pharmacology but are also presenting new therapeutic opportunities in oncological, metabolic, and infectious disease contexts.

The ongoing evolution in this field is also a reflection of deeper cross-disciplinary collaboration spanning organic chemistry, molecular biology, and clinical research. As this sector matures, the interplay between innovation, market dynamics, and regulatory landscapes promises to redefine therapeutic strategies worldwide. The following sections delve into transformative shifts in the landscape, key segmentation insights, and a range of regional and corporate influences that are guiding industry leaders today.

Transformative Shifts in the Cyclic Peptides Landscape

The cyclic peptides market has witnessed transformative shifts that are driving both innovation and growth. Market trends now reveal an increasing convergence of advanced synthesis techniques with state-of-the-art screening methods, leading to rapid discovery cycles and accelerated product development. Pioneering technological advancements, such as improvements in liquid-phase and solid-phase synthesis, are redefining how peptides are produced and tailored for specific clinical needs.

Beyond technological innovations, the sector has experienced significant regulatory evolution, further influenced by growing demand for personalized medicine and targeted therapeutic solutions. These factors have expedited the transition from traditional linear peptide models to cyclic structures that offer superior efficacy and safety profiles.

Moreover, increasing collaborations between academic research centers, biotechnology firms, and pharmaceutical companies are fostering an environment of shared expertise and risk. As these partnerships become more prevalent, the integration of interdisciplinary research and commercial insights is set to push the envelope even further. Ultimately, these shifts have not only restructured competitive landscapes but are also opening up new avenues for cost-effective, high-impact healthcare solutions that cater to evolving patient needs and industry demands.

Key Segmentation Insights for the Cyclic Peptides Market

In understanding the complex dynamics of the cyclic peptides market, a deep dive into segmentation provides critical insights on several fronts. The analysis begins with the type-based segmentation, where the market is bifurcated into natural cyclic peptides and synthetic cyclic peptides. This distinction highlights the dual sources of innovation, with natural peptides offering inherent biological compatibility and synthetic variants providing opportunities for structural modifications to enhance therapeutic efficacy.

Further segmentation based on product reveals a diverse portfolio that includes antimicrobial peptides, hormonal peptides, immunomodulating peptides, and peptide vaccines. Among these, hormonal peptides are studied in greater depth, particularly in terms of their applications in insulin analogs and peptide hormone therapy. Such detailed scrutiny helps in targeting specific therapeutic areas where peptide treatments can be further optimized.

The technological dimension of segmentation encompasses chemical synthesis, hybrid technology, liquid-phase synthesis, recombinant DNA technology, and solid-phase synthesis. Each methodology contributes uniquely by influencing product quality, scalability, and cost efficiency. In the realm of application, the market is segmented into diagnostics, environmental protection, research and development, and therapeutics. Within these broad categories, diagnostics is further dissected into biosensors and immunoassays, research and development into biochemical analysis, drug discovery, and molecular biology, while therapeutics covers a gamut that includes cardiovascular treatments, interventions for infectious diseases, metabolic disorder management, and oncology.

Finally, the segmentation based on end users sheds light on the roles played by academic institutes, biotechnology firms, and pharmaceutical companies. This layered segmentation approach not only underscores the interplay of multiple factors in determining market trends but also reinforces the importance of targeted strategies in each segment for sustainable growth and innovation.

Based on Type, market is studied across Natural Cyclic Peptide and Synthetic Cyclic Peptide.

Based on Product, market is studied across Antimicrobial Peptides, Hormonal Peptides, Immunomodulating Peptides, and Peptide Vaccines. The Hormonal Peptides is further studied across Insulin Analogs and Peptide Hormone Therapy.

Based on Technology, market is studied across Chemical Synthesis, Hybrid Technology, Liquid-Phase Synthesis, Recombinant DNA Technology, and Solid-Phase Synthesis.

Based on Application, market is studied across Diagnostics, Environmental Protection, Research & Development, and Therapeutics. The Diagnostics is further studied across Biosensors and Immunoassays. The Research & Development is further studied across Biochemical Analysis, Drug Discovery, and Molecular Biology. The Therapeutics is further studied across Cardiovascular, Infectious Diseases, Metabolic Disorders, and Oncology.

Based on End User, market is studied across Academic Institutes, Biotechnology Firms, and Pharmaceutical Companies.

Key Regional Insights Shaping the Global Market

Examining the cyclic peptides market through a regional lens reveals nuanced variations in demand, adoption, and innovation. In the Americas, robust healthcare infrastructures and a strong emphasis on biomolecular research have paved the way for dynamic market growth. This region has been at the forefront of integrating advanced synthetic methods with clinical applications, reflecting the high level of both public and private investment in biomedical research.

Turning to the Europe, Middle East & Africa region, a combination of stringent regulatory frameworks, strong academic foundations, and growing collaborative networks is rapidly transforming the landscape. Here, the focus is driven by a balance between innovation and compliance, ensuring that advancements in cyclic peptides are both cutting-edge and safe.

The Asia-Pacific region, on the other hand, is experiencing rapid expansion thanks to increasing R&D investments, progressive government initiatives, and a burgeoning pharmaceutical sector. With a blend of traditional medicinal practices and modern synthetic techniques, this region is emerging as a pivotal player in the global cyclic peptides market. Overall, the regional insights underscore a diverse yet interconnected market, where localized strategies and global trends converge to shape the future of cyclic peptides.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights in the Cyclic Peptides Sector

Leading companies in the cyclic peptides market exemplify the drive toward innovation and excellence that characterizes the industry. Industry pioneers such as Amgen Inc. and Bristol-Myers Squibb Company have invested significantly in both natural and synthetic peptide research, setting high benchmarks in therapeutic and diagnostic development. Key players including AnaSpec, Astellas Inc., and Asymchem Inc. contribute to the diversification of product portfolios by developing novel synthesis technologies and advanced drug delivery systems.

Additionally, companies like Bachem Holding AG, Clariant International Ltd, and F. Hoffmann-La Roche AG are renowned for their robust research programs that focus on optimizing peptide stability and efficacy, further cementing their roles as industry leaders. Not to be overlooked, pharmaceutical giants such as Eli Lilly and Company, GlaxoSmithKline plc, and Johnson & Johnson Services, Inc. bring valuable clinical insights that help drive regulatory and market dynamics.

Innovative firms such as Merck & Co., Inc., Novartis AG, and Sanofi S.A. continue to push the boundaries of peptide application in diverse therapeutic areas, while specialized entities like Pepscan Therapeutics B.V., PeptiDream Inc., Pfizer Inc., SciTide LLC, and Zealand Pharma AS are at the forefront of next-generation peptide research. The collective efforts of these companies are instrumental in navigating the challenges and opportunities inherent in the cyclic peptides market, paving the way for a future defined by molecular precision and transformative healthcare solutions.

The report delves into recent significant developments in the Cyclic Peptides Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AnaSpec, Astellas Inc., Asymchem Inc., Bachem Holding AG, Bristol-Myers Squibb Company, Clariant International Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Insamo, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pepscan Therapeutics B.V., PeptiDream Inc., Pfizer Inc., Sanofi S.A., SciTide LLC, and Zealand Pharma AS. Actionable Recommendations for Industry Leaders Driving Market Evolution

Industry leaders must adopt a strategic and data-driven approach to navigate the rapidly evolving cyclic peptides market. It is imperative to invest in advanced synthesis technologies and robust R&D programs that can streamline the discovery and production of new cyclic peptide formulations. By leveraging breakthroughs in liquid-phase and solid-phase synthesis, companies can accelerate development timelines and enhance product quality, ensuring a competitive edge in the global market.

Fostering strategic collaborations with academic institutions and specialized research centers is also recommended, as such partnerships can provide access to cutting-edge innovations and facilitate the translation of laboratory findings into viable commercial products. By closely monitoring segmentation trends-whether it be the evolving demands of diagnostic applications or the nuanced requirements of therapeutic interventions-organizations can align their product development strategies with market needs.

Furthermore, it is crucial to maintain agility in regulatory compliance and invest in comprehensive market research to identify emerging opportunities and potential challenges. Enhancing in-house capabilities while also exploring external strategic alliances will not only drive operational efficiency but will also bolster confidence among investors and stakeholders. In this way, industry leaders can create a resilient roadmap that capitalizes on innovation while mitigating risks in an increasingly competitive environment.

Conclusion: Embracing the Future of Cyclic Peptides

The evolution of the cyclic peptides market is a testament to the transformative potential of advanced biotechnology. With state-of-the-art synthesis technologies, a diversified segmentation strategy, and a robust network of global and regional stakeholders, this sector is poised for sustained growth and innovation. The synergies between academic excellence, corporate leadership, and regulatory foresight are creating a fertile ground for breakthrough discoveries that could redefine therapeutic paradigms.

It is evident that successful navigation of this complex market will require a keen understanding of both the scientific nuances and commercial imperatives that drive innovation. As we look to the future, the integration of multifaceted segmentation insights with strategic regional and corporate engagements will be key to unlocking the full potential of cyclic peptides. The ongoing advancements in technology and increasing cross-disciplinary collaboration underscore a promising horizon for next-generation therapeutics and diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and cancer fuels demand for innovative cyclic peptides
      • 5.1.1.2. Expansion of biopharmaceutical industry with focus on peptide therapeutics enhances cyclic peptide demand
      • 5.1.1.3. Government incentives and grants for drug development encourage exploration of cyclic peptide therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Issues with peptide stability and bioavailability
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative applications of cyclic peptides in designing environmentally sustainable agrochemicals
      • 5.1.3.2. Innovative cyclic peptide modifications to improve pharmacokinetics in therapeutic development
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of cyclic peptides
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing demand for natural cyclic peptide due to their ability to modulate biological pathways effectively
    • 5.2.2. Application: Rising application of cyclic peptides in diagnostics due to their high specificity and stability
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cyclic Peptides Market, by Type

  • 6.1. Introduction
  • 6.2. Natural Cyclic Peptide
  • 6.3. Synthetic Cyclic Peptide

7. Cyclic Peptides Market, by Product

  • 7.1. Introduction
  • 7.2. Antimicrobial Peptides
  • 7.3. Hormonal Peptides
    • 7.3.1. Insulin Analogs
    • 7.3.2. Peptide Hormone Therapy
  • 7.4. Immunomodulating Peptides
  • 7.5. Peptide Vaccines

8. Cyclic Peptides Market, by Technology

  • 8.1. Introduction
  • 8.2. Chemical Synthesis
  • 8.3. Hybrid Technology
  • 8.4. Liquid-Phase Synthesis
  • 8.5. Recombinant DNA Technology
  • 8.6. Solid-Phase Synthesis

9. Cyclic Peptides Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
    • 9.2.1. Biosensors
    • 9.2.2. Immunoassays
  • 9.3. Environmental Protection
  • 9.4. Research & Development
    • 9.4.1. Biochemical Analysis
    • 9.4.2. Drug Discovery
    • 9.4.3. Molecular Biology
  • 9.5. Therapeutics
    • 9.5.1. Cardiovascular
    • 9.5.2. Infectious Diseases
    • 9.5.3. Metabolic Disorders
    • 9.5.4. Oncology

10. Cyclic Peptides Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Institutes
  • 10.3. Biotechnology Firms
  • 10.4. Pharmaceutical Companies

11. Americas Cyclic Peptides Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cyclic Peptides Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cyclic Peptides Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Leveraging generative AI to transform peptide macrocycle design
    • 14.3.2. Novartis strengthens its footprint in cyclic peptides and radiopharmaceuticals
    • 14.3.3. Exploring Roche's breakthrough in cyclic peptide KRAS inhibitors
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AnaSpec
  • 3. Astellas Inc.
  • 4. Asymchem Inc.
  • 5. Bachem Holding AG
  • 6. Bristol-Myers Squibb Company
  • 7. Clariant International Ltd
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche AG
  • 10. GlaxoSmithKline plc
  • 11. Insamo
  • 12. Johnson & Johnson Services, Inc.
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pepscan Therapeutics B.V.
  • 16. PeptiDream Inc.
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. SciTide LLC
  • 20. Zealand Pharma AS

LIST OF FIGURES

  • FIGURE 1. CYCLIC PEPTIDES MARKET MULTI-CURRENCY
  • FIGURE 2. CYCLIC PEPTIDES MARKET MULTI-LANGUAGE
  • FIGURE 3. CYCLIC PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 4. CYCLIC PEPTIDES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CYCLIC PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CYCLIC PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CYCLIC PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CYCLIC PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY NATURAL CYCLIC PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INSULIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOMODULATING PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HYBRID TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY MOLECULAR BIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 335. QATAR CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 336. QATAR CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 342. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 343. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 344. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 345. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 349. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 350. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 351. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 352. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 353. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 354. SAUDI ARABIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 358. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 359. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 360. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 361. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 362. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 363. SOUTH AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY T